For patients with HCC that have stable disease on immunotherapy alone, would you consider adding bevacizumab at the time of disease progression and continue immunotherapy?

Given we now have multiple options for treatment of HCC in the second line setting, at present, I would favor transition to a TKI or ramucirumab. If the patient had prolonged stable disease on single-agent immunotherapy and could potentially tolerate ipilimumab/ nivolumab, I would consider this regi...

Yes, this is applicable to patients who are on single agent immunotherapy, since the atezo/bev combination carries different mechanism of synergistic potential than single agent immunotherapy. Notably, currently approved second line agents are indicated after progression on sorafenib, however, curre...